ArticleThe New England journal of medicine2018
Tolvaptan in Later-Stage Polycystic Kidney Disease.
Article in The New England journal of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A rapid automated segmentation method for total kidney volume measurement on unenhanced computed tomography in autosomal dominant polycystic kidney disease.Abdominal radiology (New York) · 2026Article
- A novel rapalog shows improved safety vs. efficacy in a human organoid model of polycystic kidney disease.Stem cell reports · 2025Article
- Long-term effect of increasing water intake on repeated self-assessed health-related quality of life (HRQoL) in autosomal dominant polycystic kidney disease.Clinical kidney journal · 2024Article
- An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKD.Kidney international reports · 2024Article
- Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease.Nature communications · 2022Article
- Drug management of autosomal dominant polycystic kidney disease.Australian prescriber · 2022Review
- Effects of Suramin on Polycystic Kidney Disease in a Mouse Model of Polycystin-1 Deficiency.International journal of molecular sciences · 2022Article
- Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling.Frontiers in molecular biosciences · 2022Review
- Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era?Kidney diseases (Basel, Switzerland) · 2019Review
- Increased salt intake does not worsen the progression of renal cystic disease in high water-loaded PCK rats.PloS one · 2019Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29385372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.